| Objective: Through checking the expression of E-cadherin, anti-apoptosis bcl-2protein in breast tissue and of sE-Cadherin in serum, the role of E-cadherin in theprogress of breast cancer will be discussed in the thesis.Method: In the first and second hospitals of Nanhua University,30cases of theadjacent normal breast tissues are selected from operative specimens as Group a(control group). Among them,30cases of mammary gland hyperplasia are selected asGroup b while70cases of breast cancer tissue as Group c. This method ofimmunohistochemistry is taken to check the expressions of E-cadherin and bcl-2inthe above tissues and the correlation between them. On the other hand, the serumsfrom30cases of healthy adult females are collected as Group A (control group); theserums from30cases of mammary gland hyperplasia are collected as Group B; theserums of30qualified cases selected from70cases of breast cancer are collected asGroup C. This method of ELISA is adopted to test the expression of sE-Cadherin inthe above serums and to analyze the correlation between the expression of serums andE-cadherin in breast tissues.Results：1. The positive expression rate of E-cadherin in normal breast Group, mammary glandhyperplasia Group and breast cancer Group is96.7%,80.0%and48.6%respectively.Compared with the positive expression rate of normal breast Group and mammarygland hyperplasia, that of breast cancer Group is low and has the obvious differences(respectively χ~2=20.839, p<0.01; χ~2=8.515，p<0.004). E-cadherin is related to cancertissue pathological grading, lymphatic metastisis and clinical TNM stage hasstatistical significance (p <0.05). But E-cadherin has no obvious relation with and patients’ age breast tumor diameter (p>0.05).2. The positive expression rate of Bcl-2in Group normal breast, mammary glandhyperplasia Group and breast cancer Group is respectively20.0%,26.7%and74.3%.Compared with the positive expression rate of normal breast Group and mammarygland hyperplasia, that of breast cancer Group is high and has the obvious differences(respectively χ~2=17.725, p<0.01; χ~2=12.931，p<0.001).3. There is a negative correlation between the positive expression rate of E-cadherinand Bcl-2in breast cancer Group (r=－0.714，p <0.05).4. The results of sE-cadherin serum level test in healthy female Group, mammarygland hyperplasia Group and breast cancer Group are respectively1.822±0.219(mg/ml)、2.228±0.267(mg/ml)、6.328±0.649(mg/ml). Compared with thesE-cadherin serum level of healthy female Group, mammary gland hyperplasia Group,that of breast cancer Group rises and has the obvious differences (respectivelyt=-19.462，p<0.001; t=-2.626，p<0.05).5. In breast cancer Group, the change of sE-cadherin level in serum is negativelycorrelated with the positive expression rate of E-cadherin in breast tissue (r=－0.766，p<0.05).Conclusions：1. The positive expression rate of E-cadherin in breast cancer tissue is significantlylower than that in the adjacent normal breast tissue and breast hyperplasia while theexpression rate of Bcl-2is significantly high. Both of them are closely related topathological grading in breast cancer, lymphatic metastasis and clinical TNM stage.Their expressions in breast cancer have a very negative correlation.2. The expression level of sE-cadherin in the serums of breast cancer patients issignificantly higher than that in benign breast hyperplasia patients and healthy adultwomen. In breast cancer group, it’s negatively correlated with the positive expressionof E-cadherin in breast tissue. Therefore, the inspection of sE-cadherin level in serumwill be expected to be the indicator of supportively diagnosing breast cancer. |
PDF Full Text Request